Pipeline Insight Lymphomas, Multiple Myeloma and Myelodysplastic Syndromes Optimization of clinical practice

The commercial success of Rituxan in the treatment of NHL and Velcade and Revlimid in the treatment of MM has attracted the interest of pharmaceutical companies to these markets. There are 173 drugs in clinical development for these indications, the majority of which are molecular targeted therapies (MTTs). This contrasts with HL and MDS where there is limited pipeline activity. Scope * Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates * Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptionsHighlights There are currently 107 drugs in clinical development for NHL, of which 12 are in late phase development. This high R&D activity is due to the diverse nature of the diseases and the success of therapies such as Rituxan in these indications. Targeted therapies account for over half of drugs in development for NHL. There are currently 15 drugs in clinical development for HL, of which 3 are in late phase development. Unmet needs persists in HL but are confined to relapsed patients and elderly patients, which are relatively small patient populations. There are currently 66 drugs in clinical development for MM, of which 8 are in late phase development. MM is an incurable disease and there is a need for better and less toxic therapies across all lines of treatment. Reasons to Purchase * Segmentation and analysis of the current pipeline by developmental phase, drug class and company * Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs